{"ticker": {"uuid": "482046b4-fa61-4eeb-83cd-8623c15479d1", "symbol": "NVSN", "name": "Novartis AG", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "summary": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:33:02+00:00", "published_display": "13 Aug 2026 15:33", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 54, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.075443, "evidence_share": 5.6, "evidence_share_display": "5.6", "freshness_pct": 98.1, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Regulation"], "evidence_basis": "", "score_included": true}, {"title": "SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T", "summary": "TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award for its subsidiary 3T. Both steps advance SBO's diversification strategy in the growing additive manufacturing market. In the US, SBO has expanded additive manufacturing capacity by adding one VELO XC and two Renishaw 500Q printers for high-performance alloys Inconel and Titanium in Q2 2026. In addition, two more VELO XC printers have been ordere", "url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "source_link": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:15:39+00:00", "published_display": "11 Aug 2026 21:15", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Operating growth"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081704, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 52.7, "age_days": 1.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["3d Printing", "Additive Manufacturing", "Aerospace", "Semiconductors", "Space"], "evidence_basis": "", "score_included": true}, {"title": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus", "summary": "Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak annual sales. Alan Bash, interim CEO following Ying Huang's departure, emphasized continuity as Wall Street's $52 consensus target sits well above current share prices. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Legend Biotech didn't make the cut. Grab the names FREE today. Sh", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:50:26+00:00", "published_display": "11 Aug 2026 16:50", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.263987, "evidence_share": 19.5, "evidence_share_display": "19.5", "freshness_pct": 75.5, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Car T", "Clinical Trials", "Earnings", "Net Income"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...", "summary": "This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up 3.4% in local currencies and order entry up 3%, maintaining a book-to-bill ratio above 1. The company's adjusted EBITDA margin improved slightly to 15.1%, despite significant headwinds from FX and tariffs, with underlying profitability up 108 basis points due to higher volumes, favorable product mix, and initial ", "url": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:00:26+00:00", "published_display": "11 Aug 2026 15:00", "source_kind": "aggregator", "sentiment": "negative", "sentiment_pct": 38, "tone_signals": ["Missed expectations", "Deteriorating financial comparison", "Margin expansion", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.14169, "evidence_share": 10.5, "evidence_share_display": "10.5", "freshness_pct": 74.7, "age_days": 2.1, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Fx", "Guidance", "Supply Chain", "Tariffs"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.128926, "evidence_share": 9.5, "evidence_share_display": "9.5", "freshness_pct": 80.6, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "M A", "Operating Income"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.117978, "evidence_share": 8.7, "evidence_share_display": "8.7", "freshness_pct": 80.5, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed", "summary": "Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights \u2013 first half of 2026 Sales of CHF 427.5 million, up 3.4% in local currencies; with growth in both Life Sciences Business (+3.1% LC) and Partnering Business (+3.6% LC) Order entry up 3.0% in local currencies, book-to-bill ratio remaining above 1 in both segments Adjusted EBITDA margin at 15.1%, with underlying profitability improvements of 180 ", "url": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "source_link": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:00:00+00:00", "published_display": "11 Aug 2026 05:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 84, "tone_signals": ["Improving financial comparison", "Margin expansion", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208025, "evidence_share": 15.4, "evidence_share_display": "15.4", "freshness_pct": 70.5, "age_days": 2.5, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Financial Results", "Guidance", "Lab Automation", "Restructuring"], "evidence_basis": "", "score_included": true}, {"title": "OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...", "summary": "This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million in total operating performance for H1 2026. Access to Space Segment Growth: Total operating performance grew by more than 30% year-on-year. Digital Segment Backlog: Increased by 70% year-on-year. Cash Flow: Positive free trade working capital cash flow with improved cash conversion, despite", "url": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T01:03:54+00:00", "published_display": "11 Aug 2026 01:03", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 85, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.20487, "evidence_share": 15.1, "evidence_share_display": "15.1", "freshness_pct": 68.9, "age_days": 2.7, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Defense", "Earnings", "Free Cash Flow", "Guidance", "M A", "Space Systems"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Storebrand Europe Index - announcement of prospectus", "summary": "Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus (\"till\u00e6g\" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq Copenhagen and is scheduled for trading on Wednesday 12 August 2026. At end of business on 7 August 2026 the fund had the following diversification characteristics for the shareclass to be listed, Storebrand Europe Index A5 \u2013 ISIN NO0013711408: Total net assets (\"Formue\"): DKK 135.524,10 Outstanding", "url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T07:25:00+00:00", "published_display": "10 Aug 2026 07:25", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019107, "evidence_share": 1.4, "evidence_share_display": "1.4", "freshness_pct": 30.5, "age_days": 3.4, "influence_label": "Low", "duplicate_count": 3, "topics": ["ESG Investing", "Equity Fund", "Europe", "Nasdaq Copenhagen", "Ucits"], "evidence_basis": "", "score_included": true}, {"title": "NOVARTIS AG Equity-to-Asset: 0.34 \u2014 26% Below Median", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OSVZYVXh3djA5dERfOWFfei1HVzJUUlZsck5PUXgyNnhrREQ0V0FLUnVvT1I1ZDhzQlFzRUNaa19EdnRfX1k0SUdacm5fNnpSd3kwSXNhWVVzVk85T25n?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OSVZYVXh3djA5dERfOWFfei1HVzJUUlZsck5PUXgyNnhrREQ0V0FLUnVvT1I1ZDhzQlFzRUNaa19EdnRfX1k0SUdacm5fNnpSd3kwSXNhWVVzVk85T25n?oc=5", "source_link_is_lookup": false, "source_name": "GuruFocus", "published_at": "2026-08-09T20:07:20+00:00", "published_display": "09 Aug 2026 20:07", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013872, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 25.9, "age_days": 3.9, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (NVS) Stock Price, News, Quote & History", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28NVS%29+Stock+Price%2C+News%2C+Quote+%26+History%22+%22Yahoo%21+Finance+Canada%22", "source_link_is_lookup": true, "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-08T14:56:39+00:00", "published_display": "08 Aug 2026 14:56", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009102, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 17.0, "age_days": 5.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis Ag (NVSN) Q4 2023 Earnings Report - Results, Call & Slides", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+Ag+%28NVSN%29+Q4+2023+Earnings+Report+-+Results%2C+Call+%26+Slides%22+%22TipRanks%22", "source_link_is_lookup": true, "source_name": "TipRanks", "published_at": "2026-08-07T21:30:04.474787+00:00", "published_display": "07 Aug 2026 21:30", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.04274, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 44.5, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22ChrysCapital+acquires+controlling+70.68%25+stake+in+Novartis+India+in+first+majority+pharma+investment%22+%22The+Economic+Times%22", "source_link_is_lookup": true, "source_name": "The Economic Times", "published_at": "2026-08-02T06:10:11.309987+00:00", "published_display": "02 Aug 2026 06:10", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032485, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 32.1, "age_days": 11.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (NVSN) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28NVSN%29+Q3+2024+Earnings+Report+-+Results%2C+Call+%26+Slides%22+%22TipRanks%22", "source_link_is_lookup": true, "source_name": "TipRanks", "published_at": "2026-07-30T10:40:01.404987+00:00", "published_display": "30 Jul 2026 10:40", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013244, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 13.8, "age_days": 14.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (TSX:NVS) Stock Price, Trades & News", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28TSX%3ANVS%29+Stock+Price%2C+Trades+%26+News%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T21:14:27.622384+00:00", "published_display": "23 Jul 2026 21:14", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 3.9e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "summary": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:33:02+00:00", "published_display": "13 Aug 2026 15:33", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "42a629e691055a42ec13ef8bc6f0f3c3d31f7b2c7e8038507a15807a75e34ff2", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.511, "provider_directional_mass": 0.046, "relevance_score": 0.636399, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 54, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.075443, "evidence_share": 5.6, "evidence_share_display": "5.6", "freshness_pct": 98.1, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Regulation"], "evidence_basis": "", "score_included": true}, {"title": "SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T", "summary": "TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award for its subsidiary 3T. Both steps advance SBO's diversification strategy in the growing additive manufacturing market. In the US, SBO has expanded additive manufacturing capacity by adding one VELO XC and two Renishaw 500Q printers for high-performance alloys Inconel and Titanium in Q2 2026. In addition, two more VELO XC printers have been ordere", "url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "source_link": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:15:39+00:00", "published_display": "11 Aug 2026 21:15", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "ea7e7c83c69cf0488590973f55b3e45a00e458be651cdf2ada60e1789a419701", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.655, "provider_directional_mass": 0.1371, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Operating growth"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081704, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 52.7, "age_days": 1.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["3d Printing", "Additive Manufacturing", "Aerospace", "Semiconductors", "Space"], "evidence_basis": "", "score_included": true}, {"title": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus", "summary": "Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak annual sales. Alan Bash, interim CEO following Ying Huang's departure, emphasized continuity as Wall Street's $52 consensus target sits well above current share prices. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Legend Biotech didn't make the cut. Grab the names FREE today. Sh", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:50:26+00:00", "published_display": "11 Aug 2026 16:50", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "f2e06038afee25fab88099f64942b11c7f011fb1a6fc0f4cc80df88cacfb7b25", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.263987, "evidence_share": 19.5, "evidence_share_display": "19.5", "freshness_pct": 75.5, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Car T", "Clinical Trials", "Earnings", "Net Income"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...", "summary": "This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up 3.4% in local currencies and order entry up 3%, maintaining a book-to-bill ratio above 1. The company's adjusted EBITDA margin improved slightly to 15.1%, despite significant headwinds from FX and tariffs, with underlying profitability up 108 basis points due to higher volumes, favorable product mix, and initial ", "url": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:00:26+00:00", "published_display": "11 Aug 2026 15:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8bff636033b9a135246cd57fe0761b00a58cc843c827483397f6e1377ad897ea", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.74, "provider_directional_mass": 0.153, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.518, "sentiment": "negative", "sentiment_pct": 38, "tone_signals": ["Missed expectations", "Deteriorating financial comparison", "Margin expansion", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.14169, "evidence_share": 10.5, "evidence_share_display": "10.5", "freshness_pct": 74.7, "age_days": 2.1, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Fx", "Guidance", "Supply Chain", "Tariffs"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "03fdb7a288edfc21b40514616b180e7d9df53c218807c001e9d74b6a285253d5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.612, "provider_directional_mass": 0.155, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.256, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.128926, "evidence_share": 9.5, "evidence_share_display": "9.5", "freshness_pct": 80.6, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "M A", "Operating Income"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "52566e8435df13cf73fa9717888920ac2672a0bb56e76834a3490f915476fab8", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.497, "provider_directional_mass": 0.156, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.117978, "evidence_share": 8.7, "evidence_share_display": "8.7", "freshness_pct": 80.5, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed", "summary": "Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights \u2013 first half of 2026 Sales of CHF 427.5 million, up 3.4% in local currencies; with growth in both Life Sciences Business (+3.1% LC) and Partnering Business (+3.6% LC) Order entry up 3.0% in local currencies, book-to-bill ratio remaining above 1 in both segments Adjusted EBITDA margin at 15.1%, with underlying profitability improvements of 180 ", "url": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "source_link": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:00:00+00:00", "published_display": "11 Aug 2026 05:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "b1d649f96dfc228ae3253969f0ea7e8c9065170c8714dd4049f8b4cab3ca9aff", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.775, "provider_directional_mass": 0.141, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 84, "tone_signals": ["Improving financial comparison", "Margin expansion", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208025, "evidence_share": 15.4, "evidence_share_display": "15.4", "freshness_pct": 70.5, "age_days": 2.5, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Financial Results", "Guidance", "Lab Automation", "Restructuring"], "evidence_basis": "", "score_included": true}, {"title": "OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...", "summary": "This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million in total operating performance for H1 2026. Access to Space Segment Growth: Total operating performance grew by more than 30% year-on-year. Digital Segment Backlog: Increased by 70% year-on-year. Cash Flow: Positive free trade working capital cash flow with improved cash conversion, despite", "url": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T01:03:54+00:00", "published_display": "11 Aug 2026 01:03", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "caa3ca6343b4a469f8c41308ea6c793ea1b8dec6c77edd11ad028fa8b67b714e", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.764, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 85, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.20487, "evidence_share": 15.1, "evidence_share_display": "15.1", "freshness_pct": 68.9, "age_days": 2.7, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Defense", "Earnings", "Free Cash Flow", "Guidance", "M A", "Space Systems"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Storebrand Europe Index - announcement of prospectus", "summary": "Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus (\"till\u00e6g\" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq Copenhagen and is scheduled for trading on Wednesday 12 August 2026. At end of business on 7 August 2026 the fund had the following diversification characteristics for the shareclass to be listed, Storebrand Europe Index A5 \u2013 ISIN NO0013711408: Total net assets (\"Formue\"): DKK 135.524,10 Outstanding", "url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T07:25:00+00:00", "published_display": "10 Aug 2026 07:25", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "1b6c75608c039ae482a7ea81916f849cb9c4e0afc0e1f524284fa77b627dde47", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.444, "provider_directional_mass": 0.075, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019107, "evidence_share": 1.4, "evidence_share_display": "1.4", "freshness_pct": 30.5, "age_days": 3.4, "influence_label": "Low", "duplicate_count": 3, "topics": ["ESG Investing", "Equity Fund", "Europe", "Nasdaq Copenhagen", "Ucits"], "evidence_basis": "", "score_included": true}, {"title": "NOVARTIS AG Equity-to-Asset: 0.34 \u2014 26% Below Median", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OSVZYVXh3djA5dERfOWFfei1HVzJUUlZsck5PUXgyNnhrREQ0V0FLUnVvT1I1ZDhzQlFzRUNaa19EdnRfX1k0SUdacm5fNnpSd3kwSXNhWVVzVk85T25n?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OSVZYVXh3djA5dERfOWFfei1HVzJUUlZsck5PUXgyNnhrREQ0V0FLUnVvT1I1ZDhzQlFzRUNaa19EdnRfX1k0SUdacm5fNnpSd3kwSXNhWVVzVk85T25n?oc=5", "source_link_is_lookup": false, "source_name": "GuruFocus", "published_at": "2026-08-09T20:07:20+00:00", "published_display": "09 Aug 2026 20:07", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "dff806da7a8868b6a2072d0185e0229c1e1161d1ea1b6afaaba9f3a4378d1cc3", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013872, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 25.9, "age_days": 3.9, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (NVS) Stock Price, News, Quote & History", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28NVS%29+Stock+Price%2C+News%2C+Quote+%26+History%22+%22Yahoo%21+Finance+Canada%22", "source_link_is_lookup": true, "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-08T14:56:39+00:00", "published_display": "08 Aug 2026 14:56", "provider": "archive", "providers": ["archive"], "source_names": ["Yahoo! Finance Canada"], "source_kind": "publisher", "story_key": "7307833ddaf068cafc52ea4c3312e3890697eb95210787ea8777b01e4d1369c9", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009102, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 17.0, "age_days": 5.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis Ag (NVSN) Q4 2023 Earnings Report - Results, Call & Slides", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+Ag+%28NVSN%29+Q4+2023+Earnings+Report+-+Results%2C+Call+%26+Slides%22+%22TipRanks%22", "source_link_is_lookup": true, "source_name": "TipRanks", "published_at": "2026-08-07T21:30:04.474787+00:00", "published_display": "07 Aug 2026 21:30", "provider": "archive", "providers": ["archive"], "source_names": ["TipRanks"], "source_kind": "publisher", "story_key": "3b145a4831ad7de3e6433030d8cb2c6f0cd819ba17153b2bd202496f88053ea2", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.04274, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 44.5, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22ChrysCapital+acquires+controlling+70.68%25+stake+in+Novartis+India+in+first+majority+pharma+investment%22+%22The+Economic+Times%22", "source_link_is_lookup": true, "source_name": "The Economic Times", "published_at": "2026-08-02T06:10:11.309987+00:00", "published_display": "02 Aug 2026 06:10", "provider": "archive", "providers": ["archive"], "source_names": ["The Economic Times"], "source_kind": "publisher", "story_key": "e585a59a00e4ae771da8327429be80de1c6df1fa9dd59b3b7cf4a9781efd5c45", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032485, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 32.1, "age_days": 11.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (NVSN) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28NVSN%29+Q3+2024+Earnings+Report+-+Results%2C+Call+%26+Slides%22+%22TipRanks%22", "source_link_is_lookup": true, "source_name": "TipRanks", "published_at": "2026-07-30T10:40:01.404987+00:00", "published_display": "30 Jul 2026 10:40", "provider": "archive", "providers": ["archive"], "source_names": ["TipRanks"], "source_kind": "publisher", "story_key": "2bf09c8fbbe27b790e0151060ced4d5412b653c139f51621f5a3deca994310f2", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013244, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 13.8, "age_days": 14.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Novartis AG (TSX:NVS) Stock Price, Trades & News", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Novartis+AG+%28TSX%3ANVS%29+Stock+Price%2C+Trades+%26+News%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T21:14:27.622384+00:00", "published_display": "23 Jul 2026 21:14", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "f0a91f747c9613bd4c0e19d0f078a0188057264da8e5842226c4f0400a5520a6", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 3.9e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.8, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 15, "total_unique": 15, "total_relevant": 15, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 9}, "raw_articles": 23, "unique_stories": 15, "duplicates_removed": 8, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 9, "archive_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 440, "call_budget": 500, "budget_used_pct": 88.0, "requests_made": 88, "last_success_at": "2026-08-13T17:31:15.814770+00:00", "newest_seen_at": "2026-08-13T17:17:04+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3173, "unmapped_mentions": 2001}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T13:10:34.183086+00:00", "durable_newest_article_at": "2026-08-11T21:15:39+00:00", "durable_story_count": 9}, "sentiment_summary": {"positive": 6, "negative": 1, "neutral": 8, "score": 63, "raw_score": 72, "total": 15, "evidence_count": 15, "effective_articles": 8.26, "information_mass": 1.353, "direct_story_count": 15, "direct_source_count": 5, "industry_story_count": 0, "sector_story_count": 0, "story_count": 15, "source_count": 5, "source_concentration": 0.8445, "direct_share": 100, "dispersion": 18, "confidence": 46, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-13T15:33:02+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.6, "count": 6}, {"event": "general", "label": "Market update", "weight": 2.9, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.37, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 1, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 9}, "raw_articles": 23, "unique_stories": 15, "duplicates_removed": 8, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 9, "archive_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 440, "call_budget": 500, "budget_used_pct": 88.0, "requests_made": 88, "last_success_at": "2026-08-13T17:31:15.814770+00:00", "newest_seen_at": "2026-08-13T17:17:04+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3173, "unmapped_mentions": 2001}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T13:10:34.183086+00:00", "durable_newest_article_at": "2026-08-11T21:15:39+00:00", "durable_story_count": 9}}, "market_context": {"has_market_context": true, "latest_close": 2677.0, "latest_week": "2026-08-07", "one_week_move": -1.2, "four_week_move": -2.4, "twelve_week_move": 4.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.171412, "market_dynamics_buy_signal": false, "relative_strength": 3.951374, "fair_value_gap": 26.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 21.5211, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, -2.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 62, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 9}, {"label": "GuruFocus", "count": 2}, {"label": "TipRanks", "count": 2}, {"label": "Yahoo! Finance Canada", "count": 1}, {"label": "The Economic Times", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 6}, {"label": "Market update", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "46/100", "tone": "neutral", "text": "8.26 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "74/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "18/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.2% over one week, -2.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent"}], "updated_at": "2026-08-13T13:10:34.183086+00:00", "detail_intelligence": {"headline": "Constructive news tone", "summary": "The score uses 15 current company stories from 5 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 63, "display": "63", "tone": "positive", "note": "Constructive news tone"}, {"label": "Confidence", "value": 46, "display": "46", "tone": "neutral", "note": "building confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "15 company stories"}, {"label": "Story agreement", "value": 82, "display": "82", "tone": "positive", "note": "18/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 27, "note": "1.353 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "5 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 66, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 82, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 16, "note": "less reliance on one publisher"}], "freshness": 66, "source_independence": 16, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-18", "label": "18 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-09", "label": "09 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 55, "tone": "neutral", "x": 863.2, "y": 125.9, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-11", "label": "11 Aug", "count": 7, "score": 76, "tone": "positive", "x": 894.8, "y": 87.7, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 54, "tone": "neutral", "x": 958.0, "y": 127.7, "volume_height": 7.4, "volume_y": 258.6}], "timeline_points": "294.7,135.0 515.8,135.0 610.6,135.0 768.5,135.0 800.1,135.0 831.7,135.0 863.2,125.9 894.8,87.7 958.0,127.7", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Tentative improvement", "tone": "neutral", "recent_score": 74, "prior_score": 51, "delta": 23, "recent_count": 8, "prior_count": 4, "volume_delta": 4, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 7}, {"label": "1 to 3 days", "count": 7, "share": 47}, {"label": "4 to 7 days", "count": 4, "share": 27}, {"label": "8 to 14 days", "count": 1, "share": 7}, {"label": "15 to 21 days", "count": 2, "share": 13}, {"label": "22 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 9, "share": 60, "score": 74, "tone": "positive"}, {"label": "GuruFocus", "count": 2, "share": 13, "score": 50, "tone": "neutral"}, {"label": "TipRanks", "count": 2, "share": 13, "score": 50, "tone": "neutral"}, {"label": "Yahoo! Finance Canada", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "The Economic Times", "count": 1, "share": 7, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 6, "share": 40, "score": 76, "tone": "positive"}, {"label": "Market update", "count": 5, "share": 33, "score": 71, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 13, "score": 64, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 7, "score": 62, "tone": "positive"}, {"label": "Analyst action", "count": 1, "share": 7, "score": 54, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 5, "share": 33}, {"label": "Guidance", "count": 4, "share": 27}, {"label": "Biotech", "count": 3, "share": 20}, {"label": "M A", "count": 2, "share": 13}, {"label": "Free Cash Flow", "count": 2, "share": 13}, {"label": "Ucits", "count": 1, "share": 7}, {"label": "Tariffs", "count": 1, "share": 7}, {"label": "Supply Chain", "count": 1, "share": 7}, {"label": "Space Systems", "count": 1, "share": 7}, {"label": "Space", "count": 1, "share": 7}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to NVSN."}, {"label": "Source breadth", "text": "The read spans 5 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 82/100."}], "tempering": [{"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "summary": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:33:02+00:00", "published_display": "13 Aug 2026 15:33", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 54, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.075443, "evidence_share": 5.6, "evidence_share_display": "5.6", "freshness_pct": 98.1, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Regulation"], "evidence_basis": "", "score_included": true}, "article_count": 15, "updated_at": "2026-08-13T13:10:34.183086+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 85.1, "label": "13 Feb 2026", "close": 2782.35, "index": 100.0}, {"x": 78.4, "y": 70.3, "label": "20 Feb 2026", "close": 2821.29, "index": 101.4}, {"x": 114.9, "y": 59.2, "label": "27 Feb 2026", "close": 2850.24, "index": 102.4}, {"x": 151.3, "y": 59.2, "label": "06 Mar 2026", "close": 2850.24, "index": 102.4}, {"x": 187.7, "y": 62.0, "label": "13 Mar 2026", "close": 2843.0, "index": 102.2}, {"x": 224.2, "y": 62.0, "label": "20 Mar 2026", "close": 2843.0, "index": 102.2}, {"x": 260.6, "y": 62.0, "label": "27 Mar 2026", "close": 2843.0, "index": 102.2}, {"x": 297.0, "y": 89.4, "label": "03 Apr 2026", "close": 2771.0, "index": 99.6}, {"x": 333.5, "y": 122.6, "label": "10 Apr 2026", "close": 2684.0, "index": 96.5}, {"x": 369.9, "y": 158.8, "label": "17 Apr 2026", "close": 2589.0, "index": 93.1}, {"x": 406.3, "y": 144.7, "label": "24 Apr 2026", "close": 2626.0, "index": 94.4}, {"x": 442.8, "y": 155.4, "label": "01 May 2026", "close": 2598.0, "index": 93.4}, {"x": 479.2, "y": 188.6, "label": "08 May 2026", "close": 2511.0, "index": 90.2}, {"x": 515.6, "y": 168.0, "label": "15 May 2026", "close": 2565.0, "index": 92.2}, {"x": 552.0, "y": 140.2, "label": "22 May 2026", "close": 2638.0, "index": 94.8}, {"x": 588.5, "y": 152.4, "label": "29 May 2026", "close": 2606.0, "index": 93.7}, {"x": 624.9, "y": 200.8, "label": "05 Jun 2026", "close": 2479.0, "index": 89.1}, {"x": 661.3, "y": 154.3, "label": "12 Jun 2026", "close": 2601.0, "index": 93.5}, {"x": 697.8, "y": 168.7, "label": "19 Jun 2026", "close": 2563.0, "index": 92.1}, {"x": 734.2, "y": 107.0, "label": "26 Jun 2026", "close": 2725.0, "index": 97.9}, {"x": 770.6, "y": 107.0, "label": "03 Jul 2026", "close": 2725.0, "index": 97.9}, {"x": 807.1, "y": 100.5, "label": "10 Jul 2026", "close": 2742.0, "index": 98.5}, {"x": 843.5, "y": 118.0, "label": "17 Jul 2026", "close": 2696.0, "index": 96.9}, {"x": 879.9, "y": 127.6, "label": "24 Jul 2026", "close": 2671.0, "index": 96.0}, {"x": 916.4, "y": 112.7, "label": "31 Jul 2026", "close": 2710.0, "index": 97.4}, {"x": 952.8, "y": 125.3, "label": "07 Aug 2026", "close": 2677.0, "index": 96.2}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 1, "close": 2725.0, "price_change": 6.3, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 44, "confidence": 26, "stories": 2, "close": 2725.0, "price_change": 0.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 16, "stories": 3, "close": 2742.0, "price_change": 0.6, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 14, "stories": 3, "close": 2696.0, "price_change": -1.7, "x": 848.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 3, "close": 2671.0, "price_change": -0.9, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 27, "stories": 4, "close": 2710.0, "price_change": 1.5, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 28, "stories": 4, "close": 2677.0, "price_change": -1.2, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,85.1 78.4,70.3 114.9,59.2 151.3,59.2 187.7,62.0 224.2,62.0 260.6,62.0 297.0,89.4 333.5,122.6 369.9,158.8 406.3,144.7 442.8,155.4 479.2,188.6 515.6,168.0 552.0,140.2 588.5,152.4 624.9,200.8 661.3,154.3 697.8,168.7 734.2,107.0 770.6,107.0 807.1,100.5 843.5,118.0 879.9,127.6 916.4,112.7 952.8,125.3", "sentiment_path": "739.4,130.0 775.8,130.0 812.3,130.0 848.7,130.0 885.1,130.0 921.6,130.0 958.0,130.0", "score_version": "evidence-v7", "price_change": -3.8, "sentiment_change": 0, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 28, "stories": 4, "close": 2677.0, "price_change": -1.2, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 27, "stories": 4, "close": 2710.0, "price_change": 1.5, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 3, "close": 2671.0, "price_change": -0.9, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 14, "stories": 3, "close": 2696.0, "price_change": -1.7, "x": 848.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 16, "stories": 3, "close": 2742.0, "price_change": 0.6, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 44, "confidence": 26, "stories": 2, "close": 2725.0, "price_change": 0.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 1, "close": 2725.0, "price_change": 6.3, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 2677.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 13, "score_change_display": "+13", "confidence_change": 18, "article_change": 7, "tone": "positive", "height": 26, "articles": 14, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 17:34", "short_label": "13 Aug", "collected_at": "2026-08-13T17:34:05.039793+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 24, "articles": 15, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 12, "span_label": "50 days", "first_score": 50, "latest_score": 62, "net_change": 12, "net_change_display": "+12", "direction": "Strengthening", "high_score": 63, "low_score": 50, "latest_confidence": 40, "confidence_change": 11, "latest_articles": 15, "article_change": 14, "latest_label": "13 Aug 17:34", "latest_evidence_label": "Measured", "chart_rows": [{"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 125.3, "y": 135.0}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 208.5, "y": 135.0}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 291.8, "y": 135.0}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 375.1, "y": 135.0}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 458.4, "y": 135.0}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 541.6, "y": 135.0}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 624.9, "y": 135.0}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 708.2, "y": 135.0}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 791.5, "y": 135.0}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 13, "score_change_display": "+13", "confidence_change": 18, "article_change": 7, "tone": "positive", "height": 26, "articles": 14, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 874.7, "y": 111.3}, {"label": "13 Aug 17:34", "short_label": "13 Aug", "collected_at": "2026-08-13T17:34:05.039793+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 24, "articles": 15, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 113.2}], "chart_points": "42.0,135.0 125.3,135.0 208.5,135.0 291.8,135.0 375.1,135.0 458.4,135.0 541.6,135.0 624.9,135.0 708.2,135.0 791.5,135.0 874.7,111.3 958.0,113.2", "changes": [{"label": "13 Aug 17:34", "short_label": "13 Aug", "collected_at": "2026-08-13T17:34:05.039793+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 24, "articles": 15, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 13, "score_change_display": "+13", "confidence_change": 18, "article_change": 7, "tone": "positive", "height": 26, "articles": 14, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 4, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}